

Table SI. Information about antibodies.

	Name	Amount of loaded protein	Dilution	Cat. no.	Supplier
Primary antibodies	LAPTM5	40 µg	1:500	bs-17100R	BIOSS
	CyclinD1	20 µg	1:500	A19038	ABclonalBiotech Co., Ltd.
	CyclinA	20 µg	1:1,000	AF0142	AffinityBiosciences, Ltd.
	CDK2	20 µg	1:1,000	A0094	ABclonalBiotech Co., Ltd.
	CDK4	20 µg	1:1,000	DF6102	AffinityBiosciences, Ltd.
	MMP2	20 µg	1:500	10373-2-AP	ProteinTechGroup, Inc.
	MMP9	20 µg	1:1,000	10375-2-AP	ProteinTechGroup, Inc.
	N-cadherin	40 µg	1:1,000	A19083	ABclonalBiotech Co., Ltd.
	E-cadherin	40 µg	1:500	A3044	ABclonalBiotech Co., Ltd.
	β-catenin	40 µg	1:500	A19657	ABclonalBiotech Co., Ltd.
	FOXP3	40 µg	1:1,000	AF6544	AffinityBiosciences, Ltd.
	Histone H3	40 µg	1:500	A2348	ABclonalBiotech Co., Ltd.
Secondary antibodies	β-actin	20/40 µg	1:1,000	sc-47778	Santa Cruz Biotechnology, Inc.
	Goat anti-rabbit IgG	20/40 µg	1:5,000	A0208	Beyotime Institute of Biotechnology
	Goat anti-mouse IgG	20/40 µg	1:5,000	A0216	Beyotime Institute of Biotechnology

β-actin was used as a loading control, and its loaded amount was consistent with the detected proteins. The secondary antibodies were incubated with proteins loaded as the above amount after the primary antibodies' treatment. Therefore, loading amount of secondary antibodies was also consistent with the detected proteins. LAPTM5, lysosomal protein transmembrane 5; FOXP3, forkhead box protein 3.

Table SII. Primer sequences of binding sites in lysosomal protein transmembrane 5 promoter.

Binding site	Primer sequence (5'→3')
Region 1	F: TTACTCCTATAAATGGAAAATC
	R: GGGAGTCTGCATTGATT
Region 2	F: CCCCTTGGTCTCATTGGC
	R: GCCCTGCTTCATTCCACA
Region 3	F: TTTTGCAGCCAGACAGAT
	R: AGGACAGACCCTAACACG

F, forward; R, reverse.